echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > AdTp: elastin-like polypeptide enhancement adeno-associated virus in Zongchao Han's research group at the University of North Carolina is expressed under pre-storage neutralizing antibody conditions

    AdTp: elastin-like polypeptide enhancement adeno-associated virus in Zongchao Han's research group at the University of North Carolina is expressed under pre-storage neutralizing antibody conditions

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gene therapy is a treatment method


    Recently, Zongchao Han's research group from the University of North Carolina used elastin-like polypeptides (ELPs) to encapsulate AAV to form nanoparticles (ELP-AAV), which enhanced the delivery of AAV and gene expression


    [Figure 1] (A) Comparison of ELP-AAV entry into cells and ordinary AAV into cells (B) Morphological comparison of ordinary AAV and ELP-AAV (C) Determination of ELP at the junction site (D) of ELP in different serotypeSAAV by MALDI-TOF Transduction efficiency of ELP-AAV on the cell line

    【Figure 2】 Transduction efficiency of cell lines under neutralizing antibody conditions for different ELP-AAV and ordinary AAV

    【Figure 3】PBS stability (B) of ELP-AAV (A) And stability of serum neutralizing antibodies (C) degradation after entering cells

    [Figure 4] Neutralizing antibody titers initiated by ELP-AAV and ordinary AAV(A) injection mice and (B-D) ELP-AAV and ordinary AAV on mouse models of pre-injected neutralizing antibodies are reported gene expression and organ distribution

    [Figure 5] ELP-AAV and ordinary AAV (A-C) reported gene expression and organ distribution on mice with pre-stored AAV immunity

    WILEY


    Thesis Information:

    Elastin-Like Polypeptides Facilitate Adeno-Associated Virus Transduction in the Presence of Pre-Existing Neutralizing Antibodies

    Kai Wang, Min Zheng, Charles Askew, Xintao Zhang, Chengwen Li, Zongchao Han*

    Advanced Therapeutics

    DOI:10.


    Click "Read the original article" in the lower left corner to view the original text


    Advanced


    Therapeutics

    Journal Introduction

    Advanced Therapeutics, Wiley's 2018 sister issue to the Advanced series, is currently covered by Scopus and the Web of Science (ESCI) and will have its first impact factor






    AdvancedScienceNews

    Wiley's official WeChat platform for scientific research information


    Long press the QR code to follow us

    Share cutting-edge information| focus on scientific research trends


    To publish research news or request information sharing, please contact: ASNChina@Wiley.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.